GRDN — Guardian Pharmacy Services, Inc. stock price, charts and financials
QT76Guardian Pharmacy Services, Inc.Guardian Pharmacy Services, Inc. (NYSE: GRDN) is a Healthcare company in the Medical - Care Facilities industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 42.85 | EPS (ttm) | 1.05 | Insider Own | - | Shs Outstand | 63.32M | Perf Week | 3.09% |
| Market Cap | 2.85B | Forward P/E | 31.46 | EPS next Y | 1.43 | Insider Trans | 0.00% | Shs Float | 51.12M | Perf Month | 18.49% |
| Enterprise Value | 2.79B | PEG | 0.15 | EPS next Q | 0.32 | Inst Own | - | Short Float | 5.95% | Perf Quarter | 6.08% |
| Income | 65.81M | P/S | 1.95 | EPS this Y | 26.54% | Inst Trans | - | Short Ratio | 7.76 | Perf Half Y | 30.82% |
| Sales | 1.46B | P/B | 11.60 | EPS next Y | 9.72% | ROA | 14.86% | Short Interest | 3.04M | Perf YTD | 49.52% |
| Book/sh | - | P/C | 28.82 | EPS next 5Y | 9.87% | ROE | 30.80% | 52W High | 48.33 -6.91% | Perf Year | 65.59% |
| Cash/sh | - | P/FCF | 35.71 | EPS past 3/5Y | 10.38% 18.77% | ROIC | 21.45% | 52W Low | 23.14 94.43% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | 24.51 | Sales past 3/5Y | 16.82% 14.51% | Gross Margin | 21.63% | Volatility | 5.21% 4.01% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 1.91 | EPS Y/Y TTM | 158.19% | Oper. Margin | 6.27% | ATR (14) | 1.87 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.33 | Sales Y/Y TTM | 19.22% | Profit Margin | 4.50% | RSI (14) | 62.75 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.65 | EPS Q/Q | 26.09% | SMA20 | 9.06% | Beta | 0.61 | Target Price | 48.00 |
| Payout | 0.00% | Debt/Eq | 0.14 | Sales Q/Q | 2.33% | SMA50 | 11.06% | Rel Volume | 6.62 | Prev Close | 45.05 |
| Employees | 3,600 | LT Debt/Eq | 0.14 | Earnings | Nov 09 | SMA200 | 23.22% | Avg Volume | 484.28K | Price | 44.99 |
| IPO Date | Sep 26, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 10.83% 3.32% | Net Debt/EBITDA | -0.48 | Volume | 3,205,599 | Change | -0.13% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | Oppenheimer | Outperform | $30 → $49 |
| Jun-17-26 | Reiterated | Truist Securities | Buy | $38 → $47 |
| Mar-12-26 | Reiterated | Raymond James | $28 → $40 | |
| Mar-12-26 | Reiterated | Truist Securities | Buy | $34 → $38 |
| Jan-14-26 | Reiterated | Stephens & Co. | Overweight | $36 |
| Nov-14-25 | Reiterated | Truist Securities | Buy | $30 → $34 |
| Oct-10-25 | Initiated | Oppenheimer | Outperform | $30 |
| Sep-26-25 | Reiterated | Truist Securities | Buy | $30 |
| May-14-25 | Reiterated | Raymond James | $25 → $28 |
Guardian Pharmacy Services, Inc. operates as a pharmaceutical service provider, delivering an extensive array of tech-driven solutions. These services are specifically crafted to enhance the care of residents within long-term health care facilities (LTCFs) across the United States. The company specializes in offering personalized clinical assistance, efficient drug distribution, and comprehensive administrative support. These provisions are particularly beneficial for individuals in less acute long-term care environments, such as assisted living communities, behavioral health centers, and group homes. To bolster its operations, the company offers Guardian Compass, a platform that generates insightful dashboards from its extensive data warehouse. This tool enables its network of local pharmacies to effectively strategize, monitor performance, and refine their business processes. Furthermore, Guardian Pharmacy Services develops dedicated GuardianShield Programs for LTCFs. The company was established in 2003 and is based in Atlanta, Georgia.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,464 | 1,449 | 1,228 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,147 | 1,167 | 984 | — | — | — | — | — | — | |
| Gross Profit | 317 | 282 | 244 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 225 | 193 | 307 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | 93 | 89 | -63 | — | — | — | — | — | — | |
| Interest Expense | 0 | 1 | 3 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 5 | -15 | 0 | — | — | — | — | — | — | |
| Net Income Before Taxes | 96 | 73 | -66 | — | — | — | — | — | — | |
| Income Taxes | 30 | 24 | 5 | — | — | — | — | — | — | |
| Consolidated Net Income | 66 | 49 | -87 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 67 | 49 | -71 | — | — | — | — | — | — | |
| Net Income | 66 | 49 | -87 | — | — | — | — | — | — | |
| EPS (Recurring) | 1.05 | 0.79 | -1.77 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.05 | 0.79 | -1.77 | — | — | — | — | — | — | |
| EPS (Diluted) | 1.03 | 0.78 | -1.77 | — | — | — | — | — | — | |
| EBITDA | 114 | 96 | -43 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 43.68 | 38.58 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.94 | 1.29 | 1.02 | — | — | — | — | — | — | |
| Gross Margin | 21.65 | 19.46 | 19.87 | — | — | — | — | — | — | |
| Operating Margin | 6.35 | 6.14 | -5.13 | — | — | — | — | — | — | |
| Net Margin | 4.51 | 3.38 | -7.08 | — | — | — | — | — | — | |
| Shares Outstanding | 63 | 62 | 62 | — | — | — | — | — | — | |
| Market Capitalization | 2,834 | 1,866 | 1,256 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Pharmacy Investors, LLC | other: Member of 10% owner group | Mar 28 '26 | Option Exercise | 0.00 | 1,413,939 | 0 | 2,449,867 | Mar 31 |
| BINDLEY WILLIAM E | director, 10 percent owner: | Mar 28 '26 | Option Exercise | 0.00 | 6,100,175 | 0 | 10,569,491 | Mar 31 |
| Forbes Kendall | See Remarks | Mar 28 '26 | Option Exercise | 0.00 | 608,570 | 0 | 1,061,826 | Mar 31 |
| Morris David K | See Remarks | Mar 28 '26 | Option Exercise | 0.00 | 641,869 | 0 | 896,341 | Mar 31 |
| Cardinal Equity Fund, L.P. | other: Member of 10% owner group | Mar 28 '26 | Option Exercise | 0.00 | 471,057 | 0 | 816,180 | Mar 31 |
| Bindley Capital Partners I, LLC | 10% Owner | Mar 28 '26 | Option Exercise | 0.00 | 6,100,175 | 0 | 10,569,491 | Mar 31 |
| Salentine Thomas J Jr | director, 10 percent owner: | Mar 28 '26 | Option Exercise | 0.00 | 6,100,175 | 0 | 10,569,491 | Mar 31 |
| Ackerman John | Director | Mar 28 '26 | Option Exercise | 0.00 | 1,884,996 | 0 | 2,449,867 | Mar 31 |
| Burke Fred | See Remarks | Mar 28 '26 | Option Exercise | 0.00 | 1,298,826 | 0 | 2,139,239 | Mar 31 |
| Pharmacy Investors, LLC | other: Member of 10% owner group | Mar 20 '26 | Sale | 29.68 | 827,636 | 24,566,306 | 1,035,928 | Mar 24 |
| Morris David K | See Remarks | Mar 20 '26 | Sale | 29.68 | 187,855 | 5,576,006 | 254,472 | Mar 24 |
| Burke Fred | See Remarks | Mar 20 '26 | Sale | 29.68 | 671,432 | 19,929,780 | 840,413 | Mar 24 |
| Forbes Kendall | See Remarks | Mar 20 '26 | Sale | 29.68 | 346,672 | 10,290,092 | 453,256 | Mar 24 |
| Cardinal Equity Fund, L.P. | other: Member of 10% owner group | Mar 20 '26 | Sale | 29.68 | 275,728 | 8,184,296 | 345,123 | Mar 24 |
| Salentine Thomas J Jr | director, 10 percent owner: | Mar 20 '26 | Sale | 29.68 | 3,570,677 | 105,986,620 | 4,469,316 | Mar 24 |